organization · Reporting owner
Invus Public Equities Advisors, LLC
Disclosed activity across 7 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC.LXRX · Entity 4970 | Director · 10% owner | May 10, 2024 | May 14, 2024 |
| Scholar Rock Holding CorpSRRK · Entity 3721 | 10% owner | December 10, 2024 | December 12, 2024 |
| Seer, Inc.SEER · Entity 6717 | 10% owner | February 01, 2021 | February 04, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LEXICON PHARMACEUTICALS, INC.
Report date May 10, 2024 · Filed May 14, 2024
Jointly reported with Artal International S.C.A., Wittouck Amaury, Artal International Management S.A., Artal Group S.A., Westend S.A., Stichting Administratiekantoor Westend, Invus Public Equities, L.P., Invus, L.P., Invus Advisors, L.L.C.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 136,180,481 |
Reported balance
After 2024-05-10 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2024-05-10 · Exercise / conversion · Acquired 57,546,100 · Balance 136,180,481 F1: On March 13, 2024, Artal International S.C.A. acquired 1,150,922 shares of Series A convertible preferred stock, $0.01 par value per share (the "Preferred Stock") of the Issuer at a price of $108.50 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock") upon receipt of shareholder approval and the satisfaction of certain other conditions (the "Conditions"); however, absent the satisfaction of such conditions, the shares were not convertible and as such, the Preferred Stock was originally reported on Table I. On May 10, 2024, all Conditions were met, and the 1,150,922 shares of Preferred Stock became derivative securities and automatically converted into 57,546,100 shares of Issuer Common Stock. F2: These securities are directly held by Artal International S.C.A. F5: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. The Geneva branch of Artal International S.C.A. is the managing member of Invus Public Equities Advisors, LLC. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Amaury Wittouck is the sole member of the board of the Stichting. F6: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 3,516,214 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 3,516,214 F3: These securities are directly held by Invus Public Equities, L.P. F5: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. The Geneva branch of Artal International S.C.A. is the managing member of Invus Public Equities Advisors, LLC. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Amaury Wittouck is the sole member of the board of the Stichting. F6: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 35,402,689 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 35,402,689 F4: These securities are directly held by Invus, L.P. F5: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. The Geneva branch of Artal International S.C.A. is the managing member of Invus Public Equities Advisors, LLC. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Amaury Wittouck is the sole member of the board of the Stichting. F6: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnotes | 1,150,922 |
Reported balance
After 2024-05-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-05-10 · Grant · Acquired 1,150,922 · Balance 1,150,922 F1: On March 13, 2024, Artal International S.C.A. acquired 1,150,922 shares of Series A convertible preferred stock, $0.01 par value per share (the "Preferred Stock") of the Issuer at a price of $108.50 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock") upon receipt of shareholder approval and the satisfaction of certain other conditions (the "Conditions"); however, absent the satisfaction of such conditions, the shares were not convertible and as such, the Preferred Stock was originally reported on Table I. On May 10, 2024, all Conditions were met, and the 1,150,922 shares of Preferred Stock became derivative securities and automatically converted into 57,546,100 shares of Issuer Common Stock. F2: These securities are directly held by Artal International S.C.A. F5: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. The Geneva branch of Artal International S.C.A. is the managing member of Invus Public Equities Advisors, LLC. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Amaury Wittouck is the sole member of the board of the Stichting. F6: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnotes | 0 |
Reported balance
After 2024-05-10 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-05-10 · Exercise / conversion · Disposed 1,150,922 · Balance 0 F1: On March 13, 2024, Artal International S.C.A. acquired 1,150,922 shares of Series A convertible preferred stock, $0.01 par value per share (the "Preferred Stock") of the Issuer at a price of $108.50 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock") upon receipt of shareholder approval and the satisfaction of certain other conditions (the "Conditions"); however, absent the satisfaction of such conditions, the shares were not convertible and as such, the Preferred Stock was originally reported on Table I. On May 10, 2024, all Conditions were met, and the 1,150,922 shares of Preferred Stock became derivative securities and automatically converted into 57,546,100 shares of Issuer Common Stock. F2: These securities are directly held by Artal International S.C.A. F5: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. The Geneva branch of Artal International S.C.A. is the managing member of Invus Public Equities Advisors, LLC. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Amaury Wittouck is the sole member of the board of the Stichting. F6: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 13, 2024, Artal International S.C.A. acquired 1,150,922 shares of Series A convertible preferred stock, $0.01 par value per share (the "Preferred Stock") of the Issuer at a price of $108.50 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock") upon receipt of shareholder approval and the satisfaction of certain other conditions (the "Conditions"); however, absent the satisfaction of such conditions, the shares were not convertible and as such, the Preferred Stock was originally reported on Table I. On May 10, 2024, all Conditions were met, and the 1,150,922 shares of Preferred Stock became derivative securities and automatically converted into 57,546,100 shares of Issuer Common Stock.
F2: These securities are directly held by Artal International S.C.A.
F3: These securities are directly held by Invus Public Equities, L.P.
F4: These securities are directly held by Invus, L.P.
F5: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. The Geneva branch of Artal International S.C.A. is the managing member of Invus Public Equities Advisors, LLC. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Amaury Wittouck is the sole member of the board of the Stichting.
F6: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.
Scholar Rock Holding Corp
Report date December 10, 2024 · Filed December 12, 2024
Jointly reported with Invus Public Equities, L.P., Siren, L.L.C., Invus Global Management, LLC, DEBBANE RAYMOND
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,250,005 |
Reported balance
After 2024-12-10 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-12-10 · Sale · Disposed 1,600,000 · Balance 9,250,005 F1: The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C. F2: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C.
F2: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.
Seer, Inc.
Report date February 01, 2021 · Filed February 04, 2021
Jointly reported with Invus Public Equities, L.P., Artal Treasury Ltd, Artal International S.C.A., Artal International Management S.A., Artal Group S.A., Westend S.A., Wittouck Amaury, Stichting Administratiekantoor Westend
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 5,588,366 |
Reported balance
After 2021-02-01 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-02-01 · Sale · Disposed 252,545 · Balance 5,588,366 F1: This amount represents the $67.00 secondary public offering price per share of Class A common stock of Seer, Inc., less the underwriting discount of $2.847 per share for shares sold pursuant to an underwritten public offering. F2: The shares are held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Artal Treasury Ltd is the managing member of Invus Public Equities Advisors, LLC. Artal Treasury Ltd is a wholly owned subsidiary of the Geneva branch of Artal International S.C.A. The managing partner of Artal International S.C.A. is Artal International Management S.A., which is a wholly owned subsidiary of Artal Group S.A. Westend S.A. is the parent company of Artal Group, S.A., and the majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend ("Stichting"). Mr. Amaury Wittouck is the sole member of the board of Stichting. F3: Each of the Reporting Persons, other than Invus Public Equities L.P., disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: This amount represents the $67.00 secondary public offering price per share of Class A common stock of Seer, Inc., less the underwriting discount of $2.847 per share for shares sold pursuant to an underwritten public offering.
F2: The shares are held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Artal Treasury Ltd is the managing member of Invus Public Equities Advisors, LLC. Artal Treasury Ltd is a wholly owned subsidiary of the Geneva branch of Artal International S.C.A. The managing partner of Artal International S.C.A. is Artal International Management S.A., which is a wholly owned subsidiary of Artal Group S.A. Westend S.A. is the parent company of Artal Group, S.A., and the majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend ("Stichting"). Mr. Amaury Wittouck is the sole member of the board of Stichting.
F3: Each of the Reporting Persons, other than Invus Public Equities L.P., disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.
Past disclosures · reporting ended (4)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CRESCENT BIOPHARMA, INC.
Report date August 07, 2024 · Filed August 09, 2024
Jointly reported with Invus Public Equities, L.P., Siren, L.L.C., Invus Global Management, LLC, DEBBANE RAYMOND
Section 16 reporting ended · disclosed 2024-08-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,317,565 |
Last balance in matching sequence
After 2024-08-08 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2024-08-07 · Sale · Disposed 61,488 · Balance 6,578,438 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.175 to $0.1855 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1: The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C. F2: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Row 2 · 2024-08-08 · Sale · Disposed 260,873 · Balance 6,317,565 F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.18 to $0.1978 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1: The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C. F2: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C.
F2: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.175 to $0.1855 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.18 to $0.1978 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Generation Bio Co.
Report date June 16, 2020 · Filed June 18, 2020
Jointly reported with Invus Public Equities, L.P., Minne Pascal, Artal International S.C.A., Artal International Management S.A., Artal Group S.A., Westend S.A., Stichting Administratiekantoor Westend, Artal Treasury Ltd
Section 16 reporting ended · disclosed 2020-06-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,814,191 |
Last balance in matching sequence
After 2020-06-16 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2020-06-16 · Conversion · Acquired 2,014,191 · Balance 2,014,191 F1: On June 16, 2020, the Series B Preferred Stock automatically converted into Common Stock on approximately a 1.5546-for-one basis (when rounded to the nearest ten-thousandth) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3: The shares are held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Artal Treasury Ltd is the managing member of Invus Public Equities Advisors, LLC. Artal Treasury Ltd is a wholly owned subsidiary of the Geneva branch of Artal International S.C.A. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F4: (Continued from footnote 3) Each of the Reporting Persons, other than Invus Public Equities L.P., disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Row 2 · 2020-06-16 · Purchase · Acquired 800,000 · Balance 2,814,191 F3: The shares are held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Artal Treasury Ltd is the managing member of Invus Public Equities Advisors, LLC. Artal Treasury Ltd is a wholly owned subsidiary of the Geneva branch of Artal International S.C.A. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F4: (Continued from footnote 3) Each of the Reporting Persons, other than Invus Public Equities L.P., disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-06-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-06-16 · Conversion · Disposed 2,186,820 · Balance 0 F1: On June 16, 2020, the Series B Preferred Stock automatically converted into Common Stock on approximately a 1.5546-for-one basis (when rounded to the nearest ten-thousandth) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3: The shares are held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Artal Treasury Ltd is the managing member of Invus Public Equities Advisors, LLC. Artal Treasury Ltd is a wholly owned subsidiary of the Geneva branch of Artal International S.C.A. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F4: (Continued from footnote 3) Each of the Reporting Persons, other than Invus Public Equities L.P., disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. |
| Series C Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-06-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-06-16 · Conversion · Disposed 1,073,076 · Balance 0 F2: On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3: The shares are held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Artal Treasury Ltd is the managing member of Invus Public Equities Advisors, LLC. Artal Treasury Ltd is a wholly owned subsidiary of the Geneva branch of Artal International S.C.A. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F4: (Continued from footnote 3) Each of the Reporting Persons, other than Invus Public Equities L.P., disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 16, 2020, the Series B Preferred Stock automatically converted into Common Stock on approximately a 1.5546-for-one basis (when rounded to the nearest ten-thousandth) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
F2: On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
F3: The shares are held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Artal Treasury Ltd is the managing member of Invus Public Equities Advisors, LLC. Artal Treasury Ltd is a wholly owned subsidiary of the Geneva branch of Artal International S.C.A. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting.
F4: (Continued from footnote 3) Each of the Reporting Persons, other than Invus Public Equities L.P., disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.
Omega Therapeutics, Inc.
Report date July 30, 2021 · Filed August 03, 2021
Jointly reported with Invus Public Equities, L.P., Artal International S.C.A., Artal International Management S.A., Artal Group S.A., Westend S.A., Wittouck Amaury, Stichting Administratiekantoor Westend, Artal Treasury Ltd
Section 16 reporting ended · disclosed 2021-08-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,273,530 |
Last balance in matching sequence
After 2021-08-03 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2021-07-30 · Purchase · Acquired 75,000 · Balance 75,000 F1: The shares reported as purchased on July 30, 2021 were purchased in several transactions at actual purchase prices ranging from $16.00 to $16.2068 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F2: The shares are held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Artal Treasury Ltd is the managing member of Invus Public Equities Advisors, LLC. Artal Treasury Ltd is a wholly owned subsidiary of the Geneva branch of Artal International S.C.A. The managing partner of Artal International S.C.A. is Artal International Management S.A., which is a wholly owned subsidiary of Artal Group S.A. Westend S.A. is the parent company of Artal Group, S.A., and the majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend ("Stichting"). F3: (Continued from Footnote 2) Mr. Amaury Wittouck is the sole member of the board of Stichting. Each of the Reporting Persons, other than Invus Public Equities L.P., disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Row 2 · 2021-08-03 · Conversion · Acquired 1,323,530 · Balance 1,398,530 F4: The shares of Issuer's preferred stock had no expiration date and were convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F2: The shares are held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Artal Treasury Ltd is the managing member of Invus Public Equities Advisors, LLC. Artal Treasury Ltd is a wholly owned subsidiary of the Geneva branch of Artal International S.C.A. The managing partner of Artal International S.C.A. is Artal International Management S.A., which is a wholly owned subsidiary of Artal Group S.A. Westend S.A. is the parent company of Artal Group, S.A., and the majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend ("Stichting"). F3: (Continued from Footnote 2) Mr. Amaury Wittouck is the sole member of the board of Stichting. Each of the Reporting Persons, other than Invus Public Equities L.P., disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Row 3 · 2021-08-03 · Purchase · Acquired 875,000 · Balance 2,273,530 F2: The shares are held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Artal Treasury Ltd is the managing member of Invus Public Equities Advisors, LLC. Artal Treasury Ltd is a wholly owned subsidiary of the Geneva branch of Artal International S.C.A. The managing partner of Artal International S.C.A. is Artal International Management S.A., which is a wholly owned subsidiary of Artal Group S.A. Westend S.A. is the parent company of Artal Group, S.A., and the majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend ("Stichting"). F3: (Continued from Footnote 2) Mr. Amaury Wittouck is the sole member of the board of Stichting. Each of the Reporting Persons, other than Invus Public Equities L.P., disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-08-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-08-03 · Conversion · Disposed 5,000,000 · Balance 0 F4: The shares of Issuer's preferred stock had no expiration date and were convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F2: The shares are held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Artal Treasury Ltd is the managing member of Invus Public Equities Advisors, LLC. Artal Treasury Ltd is a wholly owned subsidiary of the Geneva branch of Artal International S.C.A. The managing partner of Artal International S.C.A. is Artal International Management S.A., which is a wholly owned subsidiary of Artal Group S.A. Westend S.A. is the parent company of Artal Group, S.A., and the majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend ("Stichting"). F3: (Continued from Footnote 2) Mr. Amaury Wittouck is the sole member of the board of Stichting. Each of the Reporting Persons, other than Invus Public Equities L.P., disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares reported as purchased on July 30, 2021 were purchased in several transactions at actual purchase prices ranging from $16.00 to $16.2068 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
F2: The shares are held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Artal Treasury Ltd is the managing member of Invus Public Equities Advisors, LLC. Artal Treasury Ltd is a wholly owned subsidiary of the Geneva branch of Artal International S.C.A. The managing partner of Artal International S.C.A. is Artal International Management S.A., which is a wholly owned subsidiary of Artal Group S.A. Westend S.A. is the parent company of Artal Group, S.A., and the majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend ("Stichting").
F3: (Continued from Footnote 2) Mr. Amaury Wittouck is the sole member of the board of Stichting. Each of the Reporting Persons, other than Invus Public Equities L.P., disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.
F4: The shares of Issuer's preferred stock had no expiration date and were convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock automatically converted into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering.
SQZ Biotechnologies Co
Report date November 03, 2020 · Filed November 04, 2020
Jointly reported with Invus Public Equities, L.P., Minne Pascal, Artal International S.C.A., Artal International Management S.A., Artal Group S.A., Westend S.A., Stichting Administratiekantoor Westend, Artal Treasury Ltd
Section 16 reporting ended · disclosed 2020-11-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,606,308 |
Last balance in matching sequence
After 2020-11-03 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2020-11-03 · Conversion · Acquired 1,141,308 · Balance 1,141,308 F1: On November 3, 2020, the Series C Convertible Preferred Stock and the Series D Convertible Preferred Stock each converted to Common Stock on a 1.0530 for 1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2: The shares are held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Artal Treasury Ltd is the managing member of Invus Public Equities Advisors, LLC. Artal Treasury Ltd is a wholly owned subsidiary of the Geneva branch of Artal International S.C.A. The managing partner of Artal International S.C.A. is Artal International Management S.A., which is a wholly owned subsidiary of Artal Group S.A. Westend S.A. is the parent company of Artal Group S.A., and the majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend ("Stichting"). F3: (Continued from Footnote 2) Mr. Pascal Minne is the sole member of the board of Stichting. Each of the Reporting Persons, other than Invus Public Equities L.P., disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Row 2 · 2020-11-03 · Purchase · Acquired 465,000 · Balance 1,606,308 F2: The shares are held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Artal Treasury Ltd is the managing member of Invus Public Equities Advisors, LLC. Artal Treasury Ltd is a wholly owned subsidiary of the Geneva branch of Artal International S.C.A. The managing partner of Artal International S.C.A. is Artal International Management S.A., which is a wholly owned subsidiary of Artal Group S.A. Westend S.A. is the parent company of Artal Group S.A., and the majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend ("Stichting"). F3: (Continued from Footnote 2) Mr. Pascal Minne is the sole member of the board of Stichting. Each of the Reporting Persons, other than Invus Public Equities L.P., disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-11-03 · Conversion · Disposed 843,490 · Balance 0 F1: On November 3, 2020, the Series C Convertible Preferred Stock and the Series D Convertible Preferred Stock each converted to Common Stock on a 1.0530 for 1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2: The shares are held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Artal Treasury Ltd is the managing member of Invus Public Equities Advisors, LLC. Artal Treasury Ltd is a wholly owned subsidiary of the Geneva branch of Artal International S.C.A. The managing partner of Artal International S.C.A. is Artal International Management S.A., which is a wholly owned subsidiary of Artal Group S.A. Westend S.A. is the parent company of Artal Group S.A., and the majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend ("Stichting"). F3: (Continued from Footnote 2) Mr. Pascal Minne is the sole member of the board of Stichting. Each of the Reporting Persons, other than Invus Public Equities L.P., disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. |
| Series D Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-11-03 · Conversion · Disposed 240,375 · Balance 0 F1: On November 3, 2020, the Series C Convertible Preferred Stock and the Series D Convertible Preferred Stock each converted to Common Stock on a 1.0530 for 1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2: The shares are held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Artal Treasury Ltd is the managing member of Invus Public Equities Advisors, LLC. Artal Treasury Ltd is a wholly owned subsidiary of the Geneva branch of Artal International S.C.A. The managing partner of Artal International S.C.A. is Artal International Management S.A., which is a wholly owned subsidiary of Artal Group S.A. Westend S.A. is the parent company of Artal Group S.A., and the majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend ("Stichting"). F3: (Continued from Footnote 2) Mr. Pascal Minne is the sole member of the board of Stichting. Each of the Reporting Persons, other than Invus Public Equities L.P., disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 3, 2020, the Series C Convertible Preferred Stock and the Series D Convertible Preferred Stock each converted to Common Stock on a 1.0530 for 1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares had no expiration date.
F2: The shares are held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Artal Treasury Ltd is the managing member of Invus Public Equities Advisors, LLC. Artal Treasury Ltd is a wholly owned subsidiary of the Geneva branch of Artal International S.C.A. The managing partner of Artal International S.C.A. is Artal International Management S.A., which is a wholly owned subsidiary of Artal Group S.A. Westend S.A. is the parent company of Artal Group S.A., and the majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend ("Stichting").
F3: (Continued from Footnote 2) Mr. Pascal Minne is the sole member of the board of Stichting. Each of the Reporting Persons, other than Invus Public Equities L.P., disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 03, 2020 Filed Nov 4, 2020 01:00 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | ConversionSeries D Convertible Preferred Stock · Derivative | 240,375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-030316 · doc4.xml · derivative · entry 4 Invus Public Equities, L.P. · CIK 0001340097 · 10% owner Minne Pascal · CIK 0001460839 · 10% owner Artal International S.C.A. · CIK 0001218180 · 10% owner Artal International Management S.A. · CIK 0001522131 · 10% owner Artal Group S.A. · CIK 0001053906 · 10% owner Westend S.A. · CIK 0001283968 · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · 10% owner Artal Treasury Ltd · CIK 0001766952 · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 253,114 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On November 3, 2020, the Series C Convertible Preferred Stock and the Series D Convertible Preferred Stock each converted to Common Stock on a 1.0530 for 1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · price: On November 3, 2020, the Series C Convertible Preferred Stock and the Series D Convertible Preferred Stock each converted to Common Stock on a 1.0530 for 1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: On November 3, 2020, the Series C Convertible Preferred Stock and the Series D Convertible Preferred Stock each converted to Common Stock on a 1.0530 for 1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: On November 3, 2020, the Series C Convertible Preferred Stock and the Series D Convertible Preferred Stock each converted to Common Stock on a 1.0530 for 1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · ownership.direct: The shares are held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Artal Treasury Ltd is the managing member of Invus Public Equities Advisors, LLC. Artal Treasury Ltd is a wholly owned subsidiary of the Geneva branch of Artal International S.C.A. The managing partner of Artal International S.C.A. is Artal International Management S.A., which is a wholly owned subsidiary of Artal Group S.A. Westend S.A. is the parent company of Artal Group S.A., and the majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend ("Stichting"). F3 · ownership.direct: (Continued from Footnote 2) Mr. Pascal Minne is the sole member of the board of Stichting. Each of the Reporting Persons, other than Invus Public Equities L.P., disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 01:00 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | ConversionSeries C Convertible Preferred Stock · Derivative | 843,490 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-030316 · doc4.xml · derivative · entry 3 Invus Public Equities, L.P. · CIK 0001340097 · 10% owner Minne Pascal · CIK 0001460839 · 10% owner Artal International S.C.A. · CIK 0001218180 · 10% owner Artal International Management S.A. · CIK 0001522131 · 10% owner Artal Group S.A. · CIK 0001053906 · 10% owner Westend S.A. · CIK 0001283968 · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · 10% owner Artal Treasury Ltd · CIK 0001766952 · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 888,194 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On November 3, 2020, the Series C Convertible Preferred Stock and the Series D Convertible Preferred Stock each converted to Common Stock on a 1.0530 for 1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · price: On November 3, 2020, the Series C Convertible Preferred Stock and the Series D Convertible Preferred Stock each converted to Common Stock on a 1.0530 for 1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: On November 3, 2020, the Series C Convertible Preferred Stock and the Series D Convertible Preferred Stock each converted to Common Stock on a 1.0530 for 1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: On November 3, 2020, the Series C Convertible Preferred Stock and the Series D Convertible Preferred Stock each converted to Common Stock on a 1.0530 for 1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · ownership.direct: The shares are held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Artal Treasury Ltd is the managing member of Invus Public Equities Advisors, LLC. Artal Treasury Ltd is a wholly owned subsidiary of the Geneva branch of Artal International S.C.A. The managing partner of Artal International S.C.A. is Artal International Management S.A., which is a wholly owned subsidiary of Artal Group S.A. Westend S.A. is the parent company of Artal Group S.A., and the majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend ("Stichting"). F3 · ownership.direct: (Continued from Footnote 2) Mr. Pascal Minne is the sole member of the board of Stichting. Each of the Reporting Persons, other than Invus Public Equities L.P., disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 01:00 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | PurchaseCommon Stock | 465,000 | $16.00 | $7,440,000.00 |
DisclosureSEC source: 0000899243-20-030316 · doc4.xml · nonDerivative · entry 2 Invus Public Equities, L.P. · CIK 0001340097 · 10% owner Minne Pascal · CIK 0001460839 · 10% owner Artal International S.C.A. · CIK 0001218180 · 10% owner Artal International Management S.A. · CIK 0001522131 · 10% owner Artal Group S.A. · CIK 0001053906 · 10% owner Westend S.A. · CIK 0001283968 · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · 10% owner Artal Treasury Ltd · CIK 0001766952 · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,606,308 F2 · ownership.direct: The shares are held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Artal Treasury Ltd is the managing member of Invus Public Equities Advisors, LLC. Artal Treasury Ltd is a wholly owned subsidiary of the Geneva branch of Artal International S.C.A. The managing partner of Artal International S.C.A. is Artal International Management S.A., which is a wholly owned subsidiary of Artal Group S.A. Westend S.A. is the parent company of Artal Group S.A., and the majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend ("Stichting"). F3 · ownership.direct: (Continued from Footnote 2) Mr. Pascal Minne is the sole member of the board of Stichting. Each of the Reporting Persons, other than Invus Public Equities L.P., disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| November 03, 2020 Filed Nov 4, 2020 01:00 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | ConversionCommon Stock | 1,141,308 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-030316 · doc4.xml · nonDerivative · entry 1 Invus Public Equities, L.P. · CIK 0001340097 · 10% owner Minne Pascal · CIK 0001460839 · 10% owner Artal International S.C.A. · CIK 0001218180 · 10% owner Artal International Management S.A. · CIK 0001522131 · 10% owner Artal Group S.A. · CIK 0001053906 · 10% owner Westend S.A. · CIK 0001283968 · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · 10% owner Artal Treasury Ltd · CIK 0001766952 · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,141,308 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On November 3, 2020, the Series C Convertible Preferred Stock and the Series D Convertible Preferred Stock each converted to Common Stock on a 1.0530 for 1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · ownership.direct: The shares are held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Artal Treasury Ltd is the managing member of Invus Public Equities Advisors, LLC. Artal Treasury Ltd is a wholly owned subsidiary of the Geneva branch of Artal International S.C.A. The managing partner of Artal International S.C.A. is Artal International Management S.A., which is a wholly owned subsidiary of Artal Group S.A. Westend S.A. is the parent company of Artal Group S.A., and the majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend ("Stichting"). F3 · ownership.direct: (Continued from Footnote 2) Mr. Pascal Minne is the sole member of the board of Stichting. Each of the Reporting Persons, other than Invus Public Equities L.P., disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 22:01 UTC | Generation Bio Co. GBIO · Entity 67174 | ConversionSeries C Preferred Stock · Derivative | 1,073,076 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-017117 · doc4.xml · derivative · entry 4 Invus Public Equities, L.P. · CIK 0001340097 · 10% owner Minne Pascal · CIK 0001460839 · 10% owner Artal International S.C.A. · CIK 0001218180 · 10% owner Artal International Management S.A. · CIK 0001522131 · 10% owner Artal Group S.A. · CIK 0001053906 · 10% owner Westend S.A. · CIK 0001283968 · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · 10% owner Artal Treasury Ltd · CIK 0001766952 · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 607,527 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · derivative.exercise_date: On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · derivative.expiration_date: On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3 · ownership.direct: The shares are held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Artal Treasury Ltd is the managing member of Invus Public Equities Advisors, LLC. Artal Treasury Ltd is a wholly owned subsidiary of the Geneva branch of Artal International S.C.A. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F4 · ownership.direct: (Continued from footnote 3) Each of the Reporting Persons, other than Invus Public Equities L.P., disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 22:01 UTC | Generation Bio Co. GBIO · Entity 67174 | ConversionSeries B Preferred Stock · Derivative | 2,186,820 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-017117 · doc4.xml · derivative · entry 3 Invus Public Equities, L.P. · CIK 0001340097 · 10% owner Minne Pascal · CIK 0001460839 · 10% owner Artal International S.C.A. · CIK 0001218180 · 10% owner Artal International Management S.A. · CIK 0001522131 · 10% owner Artal Group S.A. · CIK 0001053906 · 10% owner Westend S.A. · CIK 0001283968 · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · 10% owner Artal Treasury Ltd · CIK 0001766952 · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,406,664 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On June 16, 2020, the Series B Preferred Stock automatically converted into Common Stock on approximately a 1.5546-for-one basis (when rounded to the nearest ten-thousandth) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On June 16, 2020, the Series B Preferred Stock automatically converted into Common Stock on approximately a 1.5546-for-one basis (when rounded to the nearest ten-thousandth) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On June 16, 2020, the Series B Preferred Stock automatically converted into Common Stock on approximately a 1.5546-for-one basis (when rounded to the nearest ten-thousandth) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3 · ownership.direct: The shares are held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Artal Treasury Ltd is the managing member of Invus Public Equities Advisors, LLC. Artal Treasury Ltd is a wholly owned subsidiary of the Geneva branch of Artal International S.C.A. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F4 · ownership.direct: (Continued from footnote 3) Each of the Reporting Persons, other than Invus Public Equities L.P., disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 22:01 UTC | Generation Bio Co. GBIO · Entity 67174 | PurchaseCommon Stock | 800,000 | $19.00 | $15,200,000.00 |
DisclosureSEC source: 0000899243-20-017117 · doc4.xml · nonDerivative · entry 2 Invus Public Equities, L.P. · CIK 0001340097 · 10% owner Minne Pascal · CIK 0001460839 · 10% owner Artal International S.C.A. · CIK 0001218180 · 10% owner Artal International Management S.A. · CIK 0001522131 · 10% owner Artal Group S.A. · CIK 0001053906 · 10% owner Westend S.A. · CIK 0001283968 · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · 10% owner Artal Treasury Ltd · CIK 0001766952 · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,814,191 F3 · ownership.direct: The shares are held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Artal Treasury Ltd is the managing member of Invus Public Equities Advisors, LLC. Artal Treasury Ltd is a wholly owned subsidiary of the Geneva branch of Artal International S.C.A. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F4 · ownership.direct: (Continued from footnote 3) Each of the Reporting Persons, other than Invus Public Equities L.P., disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 22:01 UTC | Generation Bio Co. GBIO · Entity 67174 | ConversionCommon Stock | 2,014,191 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-017117 · doc4.xml · nonDerivative · entry 1 Invus Public Equities, L.P. · CIK 0001340097 · 10% owner Minne Pascal · CIK 0001460839 · 10% owner Artal International S.C.A. · CIK 0001218180 · 10% owner Artal International Management S.A. · CIK 0001522131 · 10% owner Artal Group S.A. · CIK 0001053906 · 10% owner Westend S.A. · CIK 0001283968 · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · 10% owner Artal Treasury Ltd · CIK 0001766952 · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,014,191 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On June 16, 2020, the Series B Preferred Stock automatically converted into Common Stock on approximately a 1.5546-for-one basis (when rounded to the nearest ten-thousandth) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · price: On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3 · ownership.direct: The shares are held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Artal Treasury Ltd is the managing member of Invus Public Equities Advisors, LLC. Artal Treasury Ltd is a wholly owned subsidiary of the Geneva branch of Artal International S.C.A. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F4 · ownership.direct: (Continued from footnote 3) Each of the Reporting Persons, other than Invus Public Equities L.P., disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| June 28, 2018 Filed Jun 29, 2018 20:23 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 57,724 | $12.45 | $718,935.10 |
DisclosureSEC source: 0000899243-18-018727 · doc4.xml · nonDerivative · entry 2 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 3,516,214 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on June 27, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.40 to $12.60 per share and the shares reported as purchased on June 28, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.22 to $12.76 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| June 27, 2018 Filed Jun 29, 2018 20:23 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 125,114 | $12.54 | $1,568,441.62 |
DisclosureSEC source: 0000899243-18-018727 · doc4.xml · nonDerivative · entry 1 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 3,458,490 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on June 27, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.40 to $12.60 per share and the shares reported as purchased on June 28, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.22 to $12.76 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| June 25, 2018 Filed Jun 26, 2018 21:32 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 228,264 | $12.95 | $2,955,082.92 |
DisclosureSEC source: 0000899243-18-018161 · doc4.xml · nonDerivative · entry 2 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 3,333,376 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on June 22, 2018 were purchased in multiple transactions at actual purchase prices ranging from $13.14 to $13.49 per share and the shares reported as purchased on June 25, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.57 to $13.08 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| June 22, 2018 Filed Jun 26, 2018 21:32 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 25,461 | $13.36 | $340,090.22 |
DisclosureSEC source: 0000899243-18-018161 · doc4.xml · nonDerivative · entry 1 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 3,105,112 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on June 22, 2018 were purchased in multiple transactions at actual purchase prices ranging from $13.14 to $13.49 per share and the shares reported as purchased on June 25, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.57 to $13.08 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| June 21, 2018 Filed Jun 21, 2018 21:55 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 51,600 | $13.27 | $684,613.32 |
DisclosureSEC source: 0000899243-18-017617 · doc4.xml · nonDerivative · entry 3 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 3,079,651 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on June 19, 2018 were purchased in multiple transactions at actual purchase prices ranging from $13.38 to $13.50 per share, the shares reported as purchased on June 20, 2018 were purchased in multiple transactions at actual purchase prices ranging from $13.22 to $13.30 per share, and the shares reported as purchased on June 21, 2018 were purchased in multiple transactions at actual purchase prices ranging from $13.12 to $13.52 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| June 20, 2018 Filed Jun 21, 2018 21:55 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 12,391 | $13.28 | $164,613.20 |
DisclosureSEC source: 0000899243-18-017617 · doc4.xml · nonDerivative · entry 2 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 3,028,051 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on June 19, 2018 were purchased in multiple transactions at actual purchase prices ranging from $13.38 to $13.50 per share, the shares reported as purchased on June 20, 2018 were purchased in multiple transactions at actual purchase prices ranging from $13.22 to $13.30 per share, and the shares reported as purchased on June 21, 2018 were purchased in multiple transactions at actual purchase prices ranging from $13.12 to $13.52 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| June 19, 2018 Filed Jun 21, 2018 21:55 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 8,982 | $13.45 | $120,818.68 |
DisclosureSEC source: 0000899243-18-017617 · doc4.xml · nonDerivative · entry 1 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 3,015,660 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on June 19, 2018 were purchased in multiple transactions at actual purchase prices ranging from $13.38 to $13.50 per share, the shares reported as purchased on June 20, 2018 were purchased in multiple transactions at actual purchase prices ranging from $13.22 to $13.30 per share, and the shares reported as purchased on June 21, 2018 were purchased in multiple transactions at actual purchase prices ranging from $13.12 to $13.52 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| June 18, 2018 Filed Jun 18, 2018 22:56 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 36,584 | $13.06 | $477,937.03 |
DisclosureSEC source: 0000899243-18-017071 · doc4.xml · nonDerivative · entry 2 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 3,006,678 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on June 14, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.575 to $12.79 per share and the shares reported as purchased on June 18, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.95 to $13.10 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 22:56 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 9,200 | $12.66 | $116,461.88 |
DisclosureSEC source: 0000899243-18-017071 · doc4.xml · nonDerivative · entry 1 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 2,970,094 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on June 14, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.575 to $12.79 per share and the shares reported as purchased on June 18, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.95 to $13.10 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| June 12, 2018 Filed Jun 12, 2018 22:10 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 107,023 | $12.83 | $1,373,244.22 |
DisclosureSEC source: 0000899243-18-016245 · doc4.xml · nonDerivative · entry 3 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 2,960,894 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on June 8, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.60 to $13.03 per share, the shares reported as purchased on June 11, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.60 to $12.99 per share, and the shares reported as purchased on June 12, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.63 to $12.95 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| June 11, 2018 Filed Jun 12, 2018 22:10 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 98,626 | $12.75 | $1,257,451.91 |
DisclosureSEC source: 0000899243-18-016245 · doc4.xml · nonDerivative · entry 2 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 2,853,871 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on June 8, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.60 to $13.03 per share, the shares reported as purchased on June 11, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.60 to $12.99 per share, and the shares reported as purchased on June 12, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.63 to $12.95 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| June 08, 2018 Filed Jun 12, 2018 22:10 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 29,747 | $12.89 | $383,426.93 |
DisclosureSEC source: 0000899243-18-016245 · doc4.xml · nonDerivative · entry 1 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 2,755,245 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on June 8, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.60 to $13.03 per share, the shares reported as purchased on June 11, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.60 to $12.99 per share, and the shares reported as purchased on June 12, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.63 to $12.95 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| June 07, 2018 Filed Jun 7, 2018 23:37 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 57,439 | $12.93 | $742,508.21 |
DisclosureSEC source: 0000899243-18-015606 · doc4.xml · nonDerivative · entry 3 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 2,725,498 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on June 5, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.10 to $12.73 per share, the shares reported as purchased on June 6, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.32 to $12.76 per share, and the shares reported as purchased on June 7, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.61 to $13.06 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| June 06, 2018 Filed Jun 7, 2018 23:37 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 95,079 | $12.58 | $1,196,369.55 |
DisclosureSEC source: 0000899243-18-015606 · doc4.xml · nonDerivative · entry 2 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 2,668,059 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on June 5, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.10 to $12.73 per share, the shares reported as purchased on June 6, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.32 to $12.76 per share, and the shares reported as purchased on June 7, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.61 to $13.06 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 23:37 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 173,121 | $12.45 | $2,156,187.43 |
DisclosureSEC source: 0000899243-18-015606 · doc4.xml · nonDerivative · entry 1 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 2,572,980 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on June 5, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.10 to $12.73 per share, the shares reported as purchased on June 6, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.32 to $12.76 per share, and the shares reported as purchased on June 7, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.61 to $13.06 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| June 04, 2018 Filed Jun 4, 2018 21:31 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 121,803 | $12.24 | $1,490,576.39 |
DisclosureSEC source: 0000899243-18-014948 · doc4.xml · nonDerivative · entry 3 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 2,399,859 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on May 31, 2018 were purchased in multiple transactions at actual purchase prices ranging from $10.59 to $12.00 per share, the shares reported as purchased on June 1, 2018 were purchased in multiple transactions at actual purchase prices ranging from $11.50 to $12.62 per share, and the shares reported as purchased on June 4, 2018 were purchased in multiple transactions at actual purchase prices ranging from $11.82 to $12.39 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 21:31 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 147,339 | $12.22 | $1,800,040.56 |
DisclosureSEC source: 0000899243-18-014948 · doc4.xml · nonDerivative · entry 2 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 2,278,056 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on May 31, 2018 were purchased in multiple transactions at actual purchase prices ranging from $10.59 to $12.00 per share, the shares reported as purchased on June 1, 2018 were purchased in multiple transactions at actual purchase prices ranging from $11.50 to $12.62 per share, and the shares reported as purchased on June 4, 2018 were purchased in multiple transactions at actual purchase prices ranging from $11.82 to $12.39 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 21:31 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 147,339 | $11.62 | $1,712,049.71 |
DisclosureSEC source: 0000899243-18-014948 · doc4.xml · nonDerivative · entry 1 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 2,130,717 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on May 31, 2018 were purchased in multiple transactions at actual purchase prices ranging from $10.59 to $12.00 per share, the shares reported as purchased on June 1, 2018 were purchased in multiple transactions at actual purchase prices ranging from $11.50 to $12.62 per share, and the shares reported as purchased on June 4, 2018 were purchased in multiple transactions at actual purchase prices ranging from $11.82 to $12.39 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| May 30, 2018 Filed May 31, 2018 00:53 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 147,339 | $10.32 | $1,521,024.70 |
DisclosureSEC source: 0000899243-18-014494 · doc4.xml · nonDerivative · entry 3 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 1,983,378 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on May 25, 2018 were purchased in multiple transactions at actual purchase prices ranging from $9.37 to $9.73 per share, the shares reported as purchased on May 29, 2018 were purchased in multiple transactions at actual purchase prices ranging from $9.45 to $10.01 per share, and the shares reported as purchased on May 30, 2018 were purchased in multiple transactions at actual purchase prices ranging from $9.82 to $10.61 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| May 29, 2018 Filed May 31, 2018 00:53 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 147,339 | $9.84 | $1,450,419.85 |
DisclosureSEC source: 0000899243-18-014494 · doc4.xml · nonDerivative · entry 2 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 1,836,039 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on May 25, 2018 were purchased in multiple transactions at actual purchase prices ranging from $9.37 to $9.73 per share, the shares reported as purchased on May 29, 2018 were purchased in multiple transactions at actual purchase prices ranging from $9.45 to $10.01 per share, and the shares reported as purchased on May 30, 2018 were purchased in multiple transactions at actual purchase prices ranging from $9.82 to $10.61 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| May 29, 2018 Filed Jun 1, 2018 01:41 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | ConversionSeries C Preferred Stock · Derivative | 5,555,556 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-037313 · a4.xml · derivative · entry 3 Artal International S.C.A. · CIK 0001218180 · 10% owner Invus Public Equities, L.P. · CIK 0001340097 · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · 10% owner Artal International Management S.A. · CIK 0001522131 · 10% owner Artal Group S.A. · CIK 0001053906 · 10% owner Westend S.A. · CIK 0001283968 · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · 10% owner Minne Pascal · CIK 0001460839 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,946,040 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock automatically converted into Common Stock, for no additional payment or consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018. F1 · kind: Each share of Preferred Stock automatically converted into Common Stock, for no additional payment or consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018. F1 · price: Each share of Preferred Stock automatically converted into Common Stock, for no additional payment or consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018. F1 · derivative.exercise_date: Each share of Preferred Stock automatically converted into Common Stock, for no additional payment or consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018. F1 · derivative.expiration_date: Each share of Preferred Stock automatically converted into Common Stock, for no additional payment or consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018. F3 · ownership.direct: These securities are directly held by Artal International S.C.A. F5 · ownership.direct: Mr. Pascal Minne is the sole member of the Board of Stichting Administratiekantoor Westend. Stichting Administratiekantoor Westend is the parent company of Westend S.A. Westend S.A. is the parent company of Artal Group S.A. Artal Group S.A. is the parent company of Artal International Management S.A., which is the managing partner of Artal International S.C.A. Artal International S.C.A. is the managing member of Invus Public Equities Advisors, LLC. Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P. F6 · ownership.direct: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 29, 2018 Filed Jun 1, 2018 01:41 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | PurchaseCommon Stock | 450,000 | $14.00 | $6,300,000.00 |
DisclosureSEC source: 0001104659-18-037313 · a4.xml · nonDerivative · entry 2 Artal International S.C.A. · CIK 0001218180 · 10% owner Invus Public Equities, L.P. · CIK 0001340097 · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · 10% owner Artal International Management S.A. · CIK 0001522131 · 10% owner Artal Group S.A. · CIK 0001053906 · 10% owner Westend S.A. · CIK 0001283968 · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · 10% owner Minne Pascal · CIK 0001460839 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 450,000 F2 · kind: The shares reported as purchased on May 29, 2018 were purchased in the Issuer's initial public offering. F4 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F5 · ownership.nature: Mr. Pascal Minne is the sole member of the Board of Stichting Administratiekantoor Westend. Stichting Administratiekantoor Westend is the parent company of Westend S.A. Westend S.A. is the parent company of Artal Group S.A. Artal Group S.A. is the parent company of Artal International Management S.A., which is the managing partner of Artal International S.C.A. Artal International S.C.A. is the managing member of Invus Public Equities Advisors, LLC. Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P. F6 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 29, 2018 Filed Jun 1, 2018 01:41 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | ConversionCommon Stock | 1,946,040 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-037313 · a4.xml · nonDerivative · entry 1 Artal International S.C.A. · CIK 0001218180 · 10% owner Invus Public Equities, L.P. · CIK 0001340097 · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · 10% owner Artal International Management S.A. · CIK 0001522131 · 10% owner Artal Group S.A. · CIK 0001053906 · 10% owner Westend S.A. · CIK 0001283968 · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · 10% owner Minne Pascal · CIK 0001460839 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,946,040 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each share of Preferred Stock automatically converted into Common Stock, for no additional payment or consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018. F1 · price: Each share of Preferred Stock automatically converted into Common Stock, for no additional payment or consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018. F3 · ownership.direct: These securities are directly held by Artal International S.C.A. F5 · ownership.direct: Mr. Pascal Minne is the sole member of the Board of Stichting Administratiekantoor Westend. Stichting Administratiekantoor Westend is the parent company of Westend S.A. Westend S.A. is the parent company of Artal Group S.A. Artal Group S.A. is the parent company of Artal International Management S.A., which is the managing partner of Artal International S.C.A. Artal International S.C.A. is the managing member of Invus Public Equities Advisors, LLC. Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P. F6 · ownership.direct: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 25, 2018 Filed May 31, 2018 00:53 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 138,700 | $9.62 | $1,334,973.63 |
DisclosureSEC source: 0000899243-18-014494 · doc4.xml · nonDerivative · entry 1 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 1,688,700 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on May 25, 2018 were purchased in multiple transactions at actual purchase prices ranging from $9.37 to $9.73 per share, the shares reported as purchased on May 29, 2018 were purchased in multiple transactions at actual purchase prices ranging from $9.45 to $10.01 per share, and the shares reported as purchased on May 30, 2018 were purchased in multiple transactions at actual purchase prices ranging from $9.82 to $10.61 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| November 17, 2017 Filed Nov 18, 2017 01:09 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 50,000 | $9.85 | $492,500.00 |
DisclosureSEC source: 0000899243-17-026881 · doc4.xml · nonDerivative · entry 2 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 1,550,000 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| November 15, 2017 Filed Nov 18, 2017 01:09 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 130,727 | $10.21 | $1,334,395.85 |
DisclosureSEC source: 0000899243-17-026881 · doc4.xml · nonDerivative · entry 1 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 1,500,000 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on November 15, 2017 were purchased in multiple transactions at actual purchase prices ranging from $9.75 to $10.49 per share. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| November 14, 2017 Filed Nov 15, 2017 00:32 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 215,133 | $9.47 | $2,037,847.34 |
DisclosureSEC source: 0000899243-17-026246 · doc4.xml · nonDerivative · entry 3 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 1,369,273 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on November 10, 2017 were purchased in multiple transactions at actual purchase prices ranging from $9.12 to $9.98 per share, the shares reported as purchased on November 13, 2017 were purchased in multiple transactions at actual purchase prices ranging from $9.50 to $9.83 per share, and the shares reported as purchased on November 14, 2017 were purchased in multiple transactions at actual purchase prices ranging from $9.23 to $9.68 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| November 13, 2017 Filed Nov 15, 2017 00:32 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 215,133 | $9.75 | $2,097,933.99 |
DisclosureSEC source: 0000899243-17-026246 · doc4.xml · nonDerivative · entry 2 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 1,154,140 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on November 10, 2017 were purchased in multiple transactions at actual purchase prices ranging from $9.12 to $9.98 per share, the shares reported as purchased on November 13, 2017 were purchased in multiple transactions at actual purchase prices ranging from $9.50 to $9.83 per share, and the shares reported as purchased on November 14, 2017 were purchased in multiple transactions at actual purchase prices ranging from $9.23 to $9.68 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| November 10, 2017 Filed Nov 15, 2017 00:32 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 145,680 | $9.74 | $1,418,384.18 |
DisclosureSEC source: 0000899243-17-026246 · doc4.xml · nonDerivative · entry 1 Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner Artal International S.C.A. · CIK 0001218180 · Director · 10% owner Artal International Management S.A. · CIK 0001522131 · Director · 10% owner Artal Group S.A. · CIK 0001053906 · Director · 10% owner Westend S.A. · CIK 0001283968 · Director · 10% owner Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner Minne Pascal · CIK 0001460839 · Director · 10% owner Invus, L.P. · CIK 0001404570 · Director · 10% owner Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 939,007 F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The shares reported as purchased on November 10, 2017 were purchased in multiple transactions at actual purchase prices ranging from $9.12 to $9.98 per share, the shares reported as purchased on November 13, 2017 were purchased in multiple transactions at actual purchase prices ranging from $9.50 to $9.83 per share, and the shares reported as purchased on November 14, 2017 were purchased in multiple transactions at actual purchase prices ranging from $9.23 to $9.68 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P. F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting. F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.